02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
20:42 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Solid tumors Patient sample, cell culture, mouse and monkey studies suggest ERY974 , a bispecific antibody against CD3 and GPC3 , could help treat multiple types of GPC3-positive solid tumors. In tissue samples from...
22:45 , Oct 4, 2017 |  BC Extra  |  Preclinical News

Chugai team describes bispecific GPC3 antibody's efficacy

A study published Wednesday in Science Translational Medicine described a novel bispecific antibody that overcomes the "on-target, off-tumor" effects plaguing current cancer immunotherapies utilizing bispecific T-cell redirecting antibodies (TRAB). While the efficacy of current TRAB...